Company Overview and News
This is the third month I have officially tracked dividend income (in an article) for John's Traditional and Roth IRA Accounts. His combined dividend income totaled $908.43.
LMT POR RF.PRB RF.PRA SCG KMI.WS HTA O.PRF EPR.PRG LTC RF OPRF TD KMI.PRA KMI MSCA AAPL SCU KMR TD CVB BBT SHBI DUKH GD NYSE TNTTF MAIN O PACW DUK MSCA.CL CLDT OXY KMRFZ
SCANA Corporation’s (SCG - Free Report) proposed merger with Dominion Energy, Inc. (D - Free Report) recently received an important approval from the Federal Energy Regulatory Commission (FERC), which declared the deal to be consistent with public interest.
NOC SCG AY SCU AQN
Dominion Energy Inc.’s (D - Free Report) merger with SCANA Corporation (SCG - Free Report) has crossed another important regulatory hurdle with the approval of the Federal Energy Regulatory Commission ("FERC"). FERC approved the merger of the two companies, finding the deal to be consistent with public interest. However, completion of the merger is subject to pending consent from SCANA's shareholders; review and approval from the public service commissions of South and North Carolina; and authorization by the Nuclear Regulatory Commission.
DUKH POOL SCG GTT SCU DUK AQN
When push came to shove as the weekend approached, it was the bulls doing all the shoving. The S&P 500 gained 0.85% on Friday, led by Advanced Micro Devices (NASDAQ:AMD) and General Electric (NYSE:GE). The former was up 5% because, well, traders love to love AMD, while the latter made its advance thanks to some kind wordsfrom market commentator Jim Cramer.
GE GEC CMA.WS CMA SCG ITW SCU GNE AMD CMPWW
Brookfield Infrastructure Partners L.P. (BIP - Free Report) along with its institutional partners recently announced that the partnership has signed a definitive agreement for 100% acquisition stake in the Western Canadian natural gas gathering and processing business (also known as Canadian Midstream Business) of Enbridge, Inc. (ENB - Free Report) for $3.3 billion (approximately C$4.31 billion). The completion of the transaction process is subjected to regulatory approval along with a number of customary conditions.
ENB SCG SCU BIP ENB
In a world of low interest rates, investors look for yield wherever they can find it. One common choice has become high-dividend stocks. In the previous century, dividends did not compare well to bank interest rates. However, as interest rates fell in this century, many decided the equity risk of stocks was worth the higher yields that dividend stocks pay today.
KIM.PRI HCN SCG TWX WELL.PRI CTL HCN.PRJ LB KIM.PRM TWC KIM.PRL HCN.PRI KIM.PRK KIM.PRJ AMZN T SCU WELL KIM
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to SCG / SCANA Corp. on message board site Silicon Investor.
|Lighting Science Group Corporation (OTC Bulletin Board: LSCG||QSCG - German Broadband Network Provider/ recent ipo|
|Santa Cruz Gold (SCG.T)|
as of ET